activin A receptor type 2AGenealiases: ACTRII · ACVR2
Q-omics provides the consensus-scored ACVR2A profile across patient tissues and cancer cell-line models. ACVR2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACVR2A is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ACVR2A RNA expression shows 22,956 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KICH, and PDAC as cancer lineages where ACVR2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACVR2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACVR2A survival associations across molecular data types. ACVR2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACVR2A RNA expression–survival associations across cancer types. High ACVR2A expression shows unfavorable associations in KIRP and LIHC, but favorable associations in KIRC, UCS, LUAD and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACVR2A RNA expression.
This table summarizes ACVR2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ACVR2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACVR2A shows lower tumor expression in KICH, KIRC, BRCA, COAD and READ and higher tumor expression in CHOL. The KICH box plot shows higher ACVR2A RNA expression in normal versus tumor tissue (log2 FC = −1.249, t-test p < 0.001).
This table shows molecular features associated with ACVR2A in patient tissues and cancer cell lines. In patient samples, ACVR2A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACVR2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
